编号：2015-017 证券代码：300049 证券简称：福瑞股份 内蒙古福瑞医疗科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-----------------------------|-----------------------------|-----------------------------------------------------------------------------| | | | | | | √ | 特定对象调研 □分析师会议 | | 投资者关系活动类别 | □ | 媒体采访 □业绩说明会 | | | □新闻发布会 □路演活动 | | | | □ | 现场参观 □其他 （请文字说明其他活动内容） | | 参与单位名称及人员姓 | 国网英大集团 孙超 | | | 名 | | 深圳前海汇杰达理资本有限公司 解睿 | | 时间 | 2015 年 11 月 | 16 日 上午 10： 00 | | 地点 | 福瑞股份 会议室 | | | 上市公司接待人员姓名 | 董事会秘书 林欣 | | | 投资者关系活动 主要内容介绍 | 问：林总，今年完成 少 ...

Group 1: Strategic Partnerships and Investments - The company introduced three strategic shareholders, including KKR, Aobo, and Luxembourg, through capital increase and equity transfer, while maintaining control over Echosens [1] - The aim is to enhance technology and product offerings, focusing on becoming a leading company in liver assessment and diagnosis globally [2] Group 2: APP Development and User Engagement - The "Love Liver" health management APP is set to launch in May, with a target of developing 100,000 new members in the first phase and potentially activating an additional 400,000 users later [2] - The APP will facilitate communication between doctors and patients, allowing for direct interaction and feedback, enhancing patient experience and engagement [2] Group 3: Revenue and Financial Projections - Revenue from the "Love Liver" centers was approximately 15 million RMB last year, with projections of 80 million RMB for the current year [4] - The company aims to diversify its revenue streams into three areas: pharmaceutical sales, medical devices, and healthcare services, with a target of achieving a balanced revenue distribution over the next decade [4] Group 4: Market Potential and Competition - The liver disease market is significant, especially with the inclusion of fatty liver disease, which is reversible and has a large potential market [5] - The company acknowledges competition in the medical device sector but views it as a motivator for improving sales efforts and market focus [5]

Group 1: Company Transformation and Structure - In 2015, the company is undergoing a transformation towards medical services, focusing on several key areas including the establishment of 100 health management centers for liver disease [2][3]. - The company has restructured its operations, creating a pharmaceutical subsidiary in Jining, focusing on GMP and hospital formulations, while sales operations are centralized in Hohhot [2][3]. - The French subsidiary Echosens is responsible for medical diagnostic technology research and sales of medical devices [2][3]. Group 2: Financial Insights and Revenue Streams - A liver disease patient typically spends over 10,000 yuan annually on medication [3]. - The company aims to gradually increase the proportion of service revenue to a reasonable level, while maintaining stable growth in traditional pharmaceutical and instrument sales [4]. - The company has over 40 types of liver disease medications available for the health management centers [4]. Group 3: Development Plans and Collaborations - The company plans to enhance its online chronic liver management services and expand its range of liver disease medications [3]. - Collaboration with hospitals to establish health management centers is a priority, with each prefecture-level city targeted to have one center [4]. - The company provides advanced diagnostic tools like Fibroscan to partner hospitals, enhancing their academic image and reducing equipment investment [4]. Group 4: Management and Governance - The governance structure of Echosens will be improved to align with the company's strategic goals of becoming a leader in the global liver disease diagnostics industry [3]. - The management team regularly reports significant matters to ensure alignment with the company's objectives [3].

编号：2015-001 证券代码：300049 证券简称：福瑞股份 内蒙古福瑞医疗科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | |----------------------|---------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------- ...

编号：2015-002 证券代码：300049 证券简称：福瑞股份 内蒙古福瑞医疗科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |-----------------------------|----------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ...

Group 1: Company Overview and Operations - The "Love Liver for Life" management centers number approximately 130, establishing partnerships with hospitals to enhance cooperation [2] - The company aims to strengthen deep cooperation with these hospitals this year [2] - The drugstore management project is seen as an upgraded model of the "Love Liver for Life" centers [2] Group 2: Hospital Collaboration and Support - The company assists hospitals in improving discipline construction and introduces advanced medical technologies from larger hospitals [3] - It helps hospitals increase patient retention by providing more services [3] - The targeted hospitals for collaboration are mainly municipal infectious disease hospitals and comprehensive hospitals with strong liver disease departments [3] Group 3: Sales and Marketing Strategy - The existing sales system covers the entire country with a sales team of over 100 people [3] - The company plans to replicate the successful model of Baoding Infectious Disease Hospital as a demonstration for other hospitals [3] - The company is currently relying on other funds to carry out the drugstore management project until the fundraising is completed [3] Group 4: Financial and Market Insights - Baoding Infectious Disease Hospital, a secondary A-level hospital, generates an annual drug revenue of approximately 500,000 to 600,000 yuan [3] - The company has submitted materials for a non-public offering to the China Securities Regulatory Commission, which is currently under review [3] - The company has established a factory in Shenzhen for the domestic production of FibroScan devices, expected to receive registration approval by mid-next year [5] Group 5: Patient Services and Engagement - Patients at the "Love Liver for Life" centers can register, receive follow-up reminders, and communicate with doctors online [4] - The number of doctors managing patients is around 2,000, with over 150,000 patients registered, and a payment rate of approximately 10% [4] - The company offers over 100 types of drugs, covering all clinical medications for liver diseases [5]

Group 1: Financial Performance - The company's overall performance in the first half of the year showed steady growth, with revenue growth outpacing profit growth due to increased R&D expenses and IPO costs [2][3]. - Medical device sales met expectations, with the U.S. market experiencing increased growth and the European market improving, while sales in China remained stable [2][3]. - Pharmaceutical sales showed moderate growth, with both sales prices and raw material costs declining [2][3]. Group 2: Market and Strategic Developments - The company has submitted its IPO application to the Hong Kong Stock Exchange and is currently under review [2][3]. - The U.S. medical device market is large, and previous sales were significantly impacted by insurance issues, which have now been resolved [3]. - The company aims to enhance its service model through deeper collaborations with hospitals, moving beyond simple partnerships [4]. Group 3: Product and Service Innovations - Echosens is focusing on continuous development in liver disease diagnostics, with plans for strategic investments to support U.S. market expansion [3][4]. - The company is upgrading its drug agency model to enhance service delivery, aiming to use profits from pharmaceuticals to drive service upgrades [4]. - The company currently has over 100 types of agency drugs, primarily sourced from manufacturers, to meet hospital demands [4]. Group 4: Insurance and Payment Models - The company plans to integrate both basic medical insurance and commercial insurance into its medical service payment models [4]. - The focus is on collaborating with local commercial companies to enhance service delivery and meet hospital needs [4]. Group 5: Future Outlook - The company anticipates that the successful IPO will provide significant support for its development in terms of funding and technology [2][3]. - There are ongoing discussions about the potential impact of the two-invoice system on sales, but currently, no negative effects have been observed [4].

Group 1: Company Overview and Investment Activities - Inner Mongolia Furu Medical Technology Co., Ltd. is focused on long-term development, with major shareholders expressing confidence despite a low shareholding ratio [2] - The company has terminated its non-public stock issuance project but continues to advance its fundraising projects, now with closer cooperation with hospitals [2] - The company is involved in internet medical services and chronic disease management, aiming to provide more patient services [2] Group 2: Medical Services and Internet Platform - The company is still investing in liver disease management services, which are expected to contribute long-term and flexible benefits [3] - The "Love Liver for Life" internet platform is crucial for accumulating medical resources and is seen as a significant part of the medical service model [3] - The company has increased its investment in the internet medical platform since the second half of last year, with expectations for stable operations depending on healthcare policy reforms [3] Group 3: Financial Performance and Market Strategy - In 2016, the overseas medical project served over 1,000 patients, generating approximately 30 million yuan in revenue [3] - The company aims to provide comprehensive solutions for liver disease patients rather than focusing solely on drug development [4] - The company reported significant growth in sales in the U.S. market, with some growth also in China and Europe [4] Group 4: Research and Development - The company is primarily investing in the development of the FibroScan series and the construction of the internet medical platform [4] - Echosens, a major subsidiary, has seen substantial revenue growth but maintained stable profits due to increased expenses [4] - The company plans to continue using natural cordyceps as a raw material despite the lower cost of artificial alternatives [4] Group 5: Future Outlook and Strategic Partnerships - Echosens is focused on providing comprehensive solutions for liver disease diagnosis, with ongoing projects in collaboration with GE Healthcare [5] - The IPO expenses for Echosens in 2016 were over 3 million euros, with other costs impacting current profits [5] - The major shareholder is considering increasing control over the company when opportunities arise [5]

编号：2017-002 证券代码：300049 证券简称：福瑞股份 内蒙古福瑞医疗科技股份有限公司 投资者关系活动记录表 | --- | --- | --- | |---------------------------------------------------------|-----------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | 投资者关系活动类别 | □ | □新闻发布会 □路演活动 \n现场参观 □其他 （请文字说明其他活动内容） | | | | | | 参与单位名称及人员姓 | 国开证券 王雯 | | | 名 | 民生证券 刘淼 中银基金 陈哲 | | | | | | | 时间 | 2017 年 4 月 27 福瑞股份 会议 ...

Company Overview - Founded on November 26, 1998, focusing on liver disease pharmaceuticals, diagnostic equipment, and related medical services [2] - Achieved full licensing in the health industry, covering medical devices, therapeutic drugs, insurance, offline and online medical institutions, and health management [2] - Main product, Compound Turtle Shell Soft Liver Tablets, is the first anti-liver fibrosis drug approved by the National Medical Products Administration, with a market share exceeding 25% [2] Business Segments Pharmaceutical Business - Actively adjusting sales models to enhance product image and explore "drug benefit management" to improve sales resources and bargaining power [3] - The company aims to provide better health management services for liver disease patients while increasing profit margins and risk resistance [3] Diagnostic Equipment - Main product, FibroScan series, is the first non-invasive device using transient elastography technology for liver stiffness measurement, certified by CE, FDA, and CFDA [3] - In 2019, launched two new products, FibroScan HANDY and FibroScan Q, to meet diverse market needs [3] - Plans to collaborate with international pharmaceutical companies to enhance global clinical application of FibroScan [3] Medical Services - Obtained an internet hospital license in early 2020, offering comprehensive online services including consultations, prescriptions, and home delivery [3] - Focus on chronic liver disease management through online follow-ups and health education to improve patient compliance and reduce overall medical costs [3] Market Impact and Strategy - The COVID-19 pandemic has had mixed effects on company performance; plans to increase investor communication and funding for new business initiatives [4] - The French subsidiary's performance showed growth potential despite pandemic-related constraints [4] - The company is developing a fee-for-service model for diagnostic instruments, which is expected to become a significant revenue source in the long term [4] Sales Performance - In 2019, over 50% of diagnostic equipment sales revenue came from the U.S., with Europe contributing about 20% [6] - China accounted for approximately half of the Asian market sales [6] Future Directions - Emphasis on developing products suitable for grassroots medical institutions to meet diverse market demands [6] - Plans to enhance internet hospital operations and support community hospitals in providing quality medical services [7] - Continuous investment in R&D for more intelligent liver disease diagnostic products [6]